Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Trials

Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma

Phase 1

Terminated

Conditions: Stage IA Mycosis Fungoides/Sezary Syndrome
Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
Stage IIB Mycosis Fungoides/Sezary Syndrome
Recurrent Mycosis Fungoides/Sezary Syndrome
Stage IVB Mycosis Fungoides/Sezary Syndrome
Stage IIA Mycosis Fungoides/Sezary Syndrome
Stage IIIB Mycosis Fungoides/Sezary Syndrome
Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
Stage IB Mycosis Fungoides/Sezary Syndrome

Interventions: Drug: carfilzomib
Drug: romidepsin
Other: laboratory biomarker analysis

First Posted Date: 2012-11-30

Last Posted Date: 2019-08-29

Lead Sponsor: Northwestern University

Target Recruit Count: 7

Registration Number: NCT01738594

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Phase 1

Terminated

Conditions: Lymphoma

Interventions: Drug: Carfilzomib
Drug: Lenalidomide
Drug: Rituximab

First Posted Date: 2012-11-20

Last Posted Date: 2019-10-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT01729104

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Melphalan

First Posted Date: 2012-09-21

Last Posted Date: 2018-08-07

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 45

Registration Number: NCT01690143

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
UAB, Birmingham, Alabama, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States

and more 1 locations

A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2012-09-03

Last Posted Date: 2022-09-23

Lead Sponsor: Amgen

Target Recruit Count: 116

Registration Number: NCT01677858

Locations: 🇺🇸
California Cancer Associates for Research and Excellence, Fresno, California, United States
🇺🇸
James R. Berenson M.D. Inc., West Hollywood, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 30 locations

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Pomalidomide
Drug: Carfilzomib
Drug: dexamethasone
Drug: Daratumumab

First Posted Date: 2012-08-15

Last Posted Date: 2024-11-19

Lead Sponsor: University of Chicago

Target Recruit Count: 101

Registration Number: NCT01665794

Locations: 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦
University Health Network - Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

and more 2 locations

A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2012-08-09

Last Posted Date: 2017-10-18

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 29

Registration Number: NCT01660750

Locations: 🇺🇸
Samuel Oschin Comprehensive Cancer Center at Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Massachusettes Memorial, Worcester, Massachusetts, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

and more 2 locations

Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma

Phase 1

Terminated

Conditions: Leukemia, Plasma Cell
Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Melphalan
Drug: Filgrastim

First Posted Date: 2012-08-07

Last Posted Date: 2016-06-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT01658904

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Revlimid
Drug: Dexamethasone

First Posted Date: 2012-04-06

Last Posted Date: 2025-04-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 55

Registration Number: NCT01572480

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2012-04-02

Last Posted Date: 2022-11-14

Lead Sponsor: Amgen

Target Recruit Count: 929

Registration Number: NCT01568866

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇦🇺
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 238 locations

Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: carfilzomib
Drug: Dexamethasone
Drug: Clarithromycin
Drug: Lenalidomide

First Posted Date: 2012-03-21

Last Posted Date: 2024-03-26

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 74

Registration Number: NCT01559935

Locations: 🇺🇸
Weill Cornell Medical College, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy